Abstract
Adenosine is a neuromodulator that interacting with four receptors, A1, A2A, A2B and A3, is involved in the regulation of several biological functions in different organs and tissues, including the central nervous system, the cardiovascular system and the airways; many pathophysiological states are associated with changes of adenosine levels. For these reasons pharmaceutical companies and academicians performed intense efforts to obtain agonists, antagonists and allosteric enhancers selective for each adenosine receptor subtypes as potential clinical candidates. In fact, therapeutic modulation of the adenosine system could offer the possibility of a “soft” treatment of different diseases, but, due to the ubiquitous distribution of adenosine and of its receptors, the challenge in therapy development depends from specificity for the different receptor subtypes. Some A1 agonists and antagonists, very potent and selective, reached clinical trials for the treatment of different diseases. A1 agonists are clinical candidates for atrial arrhythmias, angina, type 2 diabetes and in pain management, while A1 antagonists are in study as potassium-sparing diuretics with kidney-protecting properties and in chronic heart diseases. Several reviews, recently published and herein cited, reported in detail the biological and clinical aspects of such molecules. This review focuses on the A1 adenosine receptor (A1AR) ligands, both agonists and antagonists, appeared in the literature in the last few years, together with their potential therapeutic application, pointing the attention on their chemical structures and SAR (Structure Activity Relationship) and also reporting new findings on preclinical or clinical trials of some important A1AR ligands synthesized in the past.
Keywords: Adenosine, A1 receptor, agonists, antagonists, SAR, heterocyclic compounds
Current Topics in Medicinal Chemistry
Title: A1 Receptors Ligands: Past, Present and Future Trends
Volume: 10 Issue: 9
Author(s): S. Schenone, C. Brullo, F. Musumeci, O. Bruno and M. Botta
Affiliation:
Keywords: Adenosine, A1 receptor, agonists, antagonists, SAR, heterocyclic compounds
Abstract: Adenosine is a neuromodulator that interacting with four receptors, A1, A2A, A2B and A3, is involved in the regulation of several biological functions in different organs and tissues, including the central nervous system, the cardiovascular system and the airways; many pathophysiological states are associated with changes of adenosine levels. For these reasons pharmaceutical companies and academicians performed intense efforts to obtain agonists, antagonists and allosteric enhancers selective for each adenosine receptor subtypes as potential clinical candidates. In fact, therapeutic modulation of the adenosine system could offer the possibility of a “soft” treatment of different diseases, but, due to the ubiquitous distribution of adenosine and of its receptors, the challenge in therapy development depends from specificity for the different receptor subtypes. Some A1 agonists and antagonists, very potent and selective, reached clinical trials for the treatment of different diseases. A1 agonists are clinical candidates for atrial arrhythmias, angina, type 2 diabetes and in pain management, while A1 antagonists are in study as potassium-sparing diuretics with kidney-protecting properties and in chronic heart diseases. Several reviews, recently published and herein cited, reported in detail the biological and clinical aspects of such molecules. This review focuses on the A1 adenosine receptor (A1AR) ligands, both agonists and antagonists, appeared in the literature in the last few years, together with their potential therapeutic application, pointing the attention on their chemical structures and SAR (Structure Activity Relationship) and also reporting new findings on preclinical or clinical trials of some important A1AR ligands synthesized in the past.
Export Options
About this article
Cite this article as:
Schenone S., Brullo C., Musumeci F., Bruno O. and Botta M., A1 Receptors Ligands: Past, Present and Future Trends, Current Topics in Medicinal Chemistry 2010; 10 (9) . https://dx.doi.org/10.2174/156802610791268729
DOI https://dx.doi.org/10.2174/156802610791268729 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design The Role of High-Density Lipoprotein Cholesterol in the Prevention and Possible Treatment of Cardiovascular Diseases
Current Molecular Medicine Rho Kinase: An Important Mediator of Atherosclerosis and Vascular Disease
Current Pharmaceutical Design Red Blood Cells as Modulators of T Cell Growth and Survival
Current Pharmaceutical Design Clinical Significance of the New Cardiovascular Risk Markers in Diabetes Mellitus
Current Diabetes Reviews Value of Abnormal Fetal Cardiac Axis in the Fetal Congenital Heart Disease
Current Medical Imaging Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets Preface
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Respiratory Gas Exchange During Exercise in Children with Congenital Heart Disease: Methodology and Clinical Concepts
Current Respiratory Medicine Reviews Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Current Cancer Drug Targets Sepsis: Links between Pathogen Sensing and Organ Damage
Current Pharmaceutical Design Stress Myocardial Perfusion Imaging in the Emergency Department - New Techniques for Speed and Diagnostic Accuracy
Current Cardiology Reviews Relationships of Beta2- and Beta3--Adrenoceptor Polymorphisms with Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews Unfolded Protein Response as a Therapeutic Target in Cardiovascular Disease
Current Topics in Medicinal Chemistry Treatment Considerations of Clinical Physician on Hypertension Management in Asia
Current Hypertension Reviews ADP Receptors-Targets for Developing Antithrombotic Agents
Current Pharmaceutical Design Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets
Current Pharmaceutical Design Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors
Recent Patents on Anti-Cancer Drug Discovery